Site icon The Skeptical Cardiologist

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

This was exciting news to encounter in my inbox this morning:

Wednesday, November 18, 2020 – 06:59am

Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;

170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group

Efficacy was consistent across age, gender, race and ethnicity demographics;

observed efficacy in adults over 65 years of age was over 94%

Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved

Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled;

no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%Companies plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe

The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021

“Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world”

Source: Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints | Pfizer

-ACP

Exit mobile version